Research
Healthcare
lf0’s Healthcare hub collects every equity research note on medical device and diagnostics companies, where regulatory approval cycles, reimbursement dynamics, and innovation pipelines drive long-run returns more than quarterly noise. Coverage in this sector currently includes Abbott Laboratories (ABT), Boston Scientific (BSX), and Intuitive Surgical (ISRG). lf0 revisits these names periodically as new clinical data, product launches, and competitive dynamics reshape the investment case, so each company’s archive is organized chronologically rather than as a single static snapshot.
Incyte Stock Analysis (INCY): JAKAFI Cliff Looms
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable,…
Boston Scientific Stock Analysis (BSX): Growth at a Premium
Boston Scientific (BSX) earns a Buy rating on double-digit revenue growth, expanding EBITDA, and improving free cash flow. The key question is whether management can…
Intuitive Surgical Stock Analysis (ISRG): Valuation Still Rich
Intuitive Surgical (ISRG) earns a HOLD rating as its dominant installed base and recurring revenue continue to support strong cash generation. However, the stock already…
Abbott Laboratories Stock Analysis (ABT): Valuation Limits Upside
Abbott Laboratories (ABT) is rated Hold as its diversified healthcare platform supports stability, but valuation and execution concerns cap near-term upside. Q1 2026 revenue and…